Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 12/20 | 1.00 |
| ▸ | AXL | P30530 | 1/20 | 1.00 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 1.00 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 1.00 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 3/20 | 0.87 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.87 |
| ▸ | NPC1 | O15118 | 2/20 | 0.87 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.87 |
| ▸ | HPGDS | O60760 | 1/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.71 |
| ▸ | GAA | P10253 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 1/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19051411 | 0.93 | CYP19A1 (1.00) | CYP19A1AXLPBRM1MKNK1MKNK2 | |
| SCHEMBL6649362 | 0.93 | CYP19A1 (0.87) | CYP19A1AXLPBRM1MKNK1MKNK2 | |
| SCHEMBL30128572 | 0.93 | CYP19A1 (1.00) | CYP19A1AXLPBRM1MKNK1MKNK2 | |
| SCHEMBL7495850 | 0.93 | RAB9A (1.00) | CYP19A1AXLPBRM1MKNK1MKNK2 | |
| SCHEMBL17014786 | 0.93 | CYP19A1 (1.00) | CYP19A1AXLPBRM1MKNK1MKNK2 | |
| Hydrochloric Acid SCHEMBL11452940 | 0.91 | RAB9A (0.97) | CYP19A1AXLPBRM1MKNK1MKNK2 | |
| SCHEMBL11460926 | 0.90 | RAB9A (0.94) | CYP19A1AXLPBRM1MKNK1MKNK2 | |
| SCHEMBL11473901 | 0.87 | RAB9A (0.77) | CYP19A1AXLPBRM1MKNK1MKNK2 | |
| SCHEMBL8978641 | 0.87 | CYP19A1 (0.89) | CYP19A1AXLPBRM1MKNK1MKNK2 | |
| SCHEMBL27676399 | 0.87 | RAB9A (0.77) | CYP19A1AXLPBRM1MKNK1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210246109-A1 | POTENT AND SELECTIVE INHIBITORS OF CYTOCHROME P450 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2021-08-12 | — | — | US | disclosed |
| EP-1130017-B1 | Azole derivatives and their use as superoxide radical inhibitors | OTSUKA PHARMA CO LTD (JP) | 2005-06-15 | — | — | EP | disclosed |
| EP-0934937-B1 | Azole derivatives as superoxide radical inhibitor | OTSUKA PHARMA CO LTD (JP) | 2002-02-27 | — | — | EP | disclosed |
| US-RE37556-E1 | (ALKOXYPHENYL)THIAZOLE DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2002-02-19 | — | — | US | disclosed |
| EP-1130017-A2 | Azole derivatives and their use as superoxide radical inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2001-09-05 | — | — | EP | disclosed |
| US-6080764-A | PROTECTING VARIOUS TISSUE CELLS FROM DISTURBANCES ASSOCIATED WITH ISCHEMIA AND BLOOD REPERFUSION IN HEART, BRAIN, KIDNEY, LUNG AND DIGESTIVE TRACT BY INHIBITING SUPEROXIDE-RELEASE BY NEUTROPHILIC LEUKOCYTES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2000-06-27 | — | — | US | disclosed |
| EP-0934937-A1 | Azole derivatives as superoxide radical inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1999-08-11 | — | — | EP | disclosed |
| US-5677319-A | THIAZOLE DERIVATIVE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-10-14 | — | — | US | disclosed |
| US-5643932-A | PREVENTS CELL DAMAGE AFTER ISCHEMIA AND RE-PERFUSION, SUBSTITUTED THIAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-07-01 | — | — | US | disclosed |
| EP-0513387-A1 | ACTIVE OXYGEN INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210246109-A1 | POTENT AND SELECTIVE INHIBITORS OF CYTOCHROME P450 | CYP11B1, CYP1B1, CYP27A1 | CYP19A1 11/4885AXL 4763/4885PBRM1 2191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.